26 results on '"Speiser, Daniel"'
Search Results
2. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy
- Author
-
Pasero, Christine, Speiser, Daniel E, Derré, Laurent, and Olive, Daniel
- Subjects
- *
TARGETED drug delivery , *CANCER treatment , *CELLULAR signal transduction , *CYTOKINES , *INFLAMMATION , *AUTOIMMUNE diseases - Abstract
The regulation of the immune system is controlled by many cell surface receptors. A prominent representative is the ‘molecular switch’ HVEM (herpes virus entry mediator) that can activate either proinflammatory or inhibitory signaling pathways. HVEM ligands belong to two distinct families: the TNF-related cytokines LIGHT and lymphotoxin-α, and the Ig-related membrane proteins BTLA and CD160. HVEM and its ligands have been involved in the pathogenesis of various autoimmune and inflammatory diseases, but recent reports indicate that this network may also be involved in tumor progression and resistance to immune response. Here we summarize the recent advances made regarding the knowledge on HVEM and its ligands in cancer cells, and their potential roles in tumor progression and escape to immune responses. Blockade or enhancement of these pathways may help improving cancer therapy. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
3. Immunological techniques: Ex vivo characterization of T cell-mediated immune responses in cancer
- Author
-
Speiser, Daniel E
- Published
- 2005
- Full Text
- View/download PDF
4. <atl>Sister cytotoxic CD8+ T cell clones differing in natural killer inhibitory receptor expression in human astrocytoma
- Author
-
Perrin, Gaëlle, Speiser, Daniel, Porret, Andrée, Quiquerez, Anne-Lise, Walker, Paul R., and Dietrich, Pierre-Yves
- Subjects
- *
T cell receptors , *KILLER cells , *HLA histocompatibility antigens - Abstract
Natural killer (NK) inhibitory receptors are thought to play a critical role in the regulation of cytotoxicity of NK cells and certain self-reactive T cells. In the present study, we investigated whether astrocytoma infiltrating T lymphocytes may be functionally compromised by NK receptors (NKRs). The NK inhibitory receptor CD94/NKG2A was found on a significant proportion of CD8+ astrocytoma infiltrating lymphocytes. The functional consequences of CD94/NKG2A expression were explored at the clonal level, using a T cell clone that exhibited substantial variation in the expression of this heterodimer. Triggering of CD94/NKG2A inhibited the killing properties of T cells with a high level of this receptor, but not those from T cells with a low level. Our data indicate that some astrocytoma infiltrating lymphocytes express functional inhibitory CD94/NKG2A, raising the possibility that they may represent silent T cells specific for self-antigens (Ags) expressed on tumor cells. Understanding the mechanisms of regulation of these receptors may bring new insights for optimizing an anti-tumor immune response. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
5. Sister cytotoxic CD8+ T cell clones differing in natural killer inhibitory receptor expression in human astrocytoma
- Author
-
Perrin, Gaëlle, Speiser, Daniel, Porret, Andrée, Quiquerez, Anne-Lise, Walker, Paul R, and Dietrich, Pierre-Yves
- Published
- 2002
- Full Text
- View/download PDF
6. Viral peptide specific cytotoxic T lymphocytes are of high avidity to host-MHC but only low avidity to donor-MHC after allogeneic bone marrow transplantation
- Author
-
Kyburz, Diego and Speiser, Daniel E
- Published
- 1995
- Full Text
- View/download PDF
7. Clinical Implications of CD8+ T-Cell Infiltration in Frequent and Rare Cancers.
- Author
-
Feldmeyer, Laurence, Gaide, Olivier, and Speiser, Daniel E
- Subjects
- *
ONCOGENES , *SKIN cancer , *SQUAMOUS cell carcinoma , *T cells , *CANCER patients - Abstract
Recent studies of cancer patients revealed high diversity in oncogenic mechanisms, leading to increased treatment individualization for subgroups of patients with frequent cancers. A similar development may not be possible for patients with rare cancers, such as Merkel cell carcinoma (MCC). Finding shared disease mechanisms may open new options to understanding and treating such tumors. Tumor-infiltrating CD8+ T cells are frequently associated with favorable clinical outcome in a remarkably large spectrum of cancers. In this issue, Afanasiev et al. suggest a mechanism that may hinder the tumor homing of CD8+ T cells in MCC patients. It is possible that therapeutic mobilization of anti-cancer T cells may be useful in patients who share this specific immune biological feature. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
8. The role of exhaustion in CAR T cell therapy.
- Author
-
Delgoffe, Greg M., Xu, Chenqi, Mackall, Crystal L., Green, Michael R., Gottschalk, Stephen, Speiser, Daniel E., Zehn, Dietmar, and Beavis, Paul A.
- Subjects
- *
CHIMERIC antigen receptors - Abstract
CAR T cell therapy successes are challenged by several mechanisms of resistance including the development of dysfunctional states such as exhaustion. The features of CAR T cell exhaustion, its role in limiting the efficacy of CAR T therapy in both liquid and solid malignancies, and potential strategies to overcome it are discussed. CAR T therapy successes are challenged by several mechanisms of resistance including the development of dysfunctional states such as exhaustion. The features of chimeric antigen receptor (CAR) T cell exhaustion, its role in limiting the efficacy of CAR T therapy in both liquid and solid malignancies, and potential strategies to overcome it are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Identification of a superagonist variant of the immunodominant Yellow fever virus epitope NS4b 214-222 by combinatorial peptide library screening.
- Author
-
Bovay, Amandine, Zoete, Vincent, Rizkallah, Pierre J., Beck, Konrad, Delbreil, Philippe, Speiser, Daniel E., Cole, David K., and Fuertes Marraco, Silvia A.
- Subjects
- *
YELLOW fever , *PHYTOPLASMAS , *T cell receptors , *T cells , *CLONE cells - Abstract
• We identified a 7I superagonist mutant of the NS4b214-22 Yellow Fever virus epitope. • This LLW-7I mutant was found by combinatorial peptide library screening on the NN5048 CD8 T cell clone. • The LLW-7I mutation increases T cell function yet does not impact the monomeric off-rate. • Our modeling suggests that this superior antigen sensitivity rather results from an increased pMHC complex rigidity. The CD8 T cell response to the HLA-A2-restricted epitope LLWNGPMAV (LLW) of the non-structural protein 4b of Yellow Fever Virus (YFV) is remarkably immunodominant, highly prevalent and powerful in YFV-vaccinated humans. Here we used a combinatorial peptide library screening in the context of an A2/LLW-specific CD8 T cell clone to identify a superagonist that features a methionine to isoleucine substitution at position 7. Based on in silico modeling, the functional enhancement of this LLW-7I mutation was associated with alterations in the structural dynamics of the peptide in the major histocompatibility complex (pMHC) binding with the T cell receptor (TCR). While the TCR off-rate of LLW-7I pMHC is comparable to the wild type peptide, the rigidity of the 7I peptide seems to confer less entropy loss upon TCR binding. This LLW-7I superagonist is an example of improved functionality in human CD8 T cells associated with optimized ligand rigidity for TCR binding and not with changes in TCR:pMHC off-rate kinetics. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies.
- Author
-
Bovay, Amandine, Nassiri, Sina, Maby–El Hajjami, Hélène, Marcos Mondéjar, Paula, Akondy, Rama S., Ahmed, Rafi, Lawson, Benton, Speiser, Daniel E., and Fuertes Marraco, Silvia A.
- Subjects
- *
YELLOW fever , *IMMUNE response , *VACCINATION , *VIRAL vaccines , *VACCINE effectiveness , *IMMUNOGLOBULINS , *VIRAL antibodies - Abstract
• Global immune characterization of YF-17D primary and booster vaccination. • Reduced immune responses to boost compared to priming in adult travellers. • Pre-existing neutralizing antibodies negatively correlate with virus replication. • Inverse association of pre-existing neutralizing antibodies with immune responses. Ever since its development in the 1930′s, the live-attenuated Yellow Fever virus vaccine YF-17D has been highly effective. Despite the increasing knowledge on the immune biology of the YF-17D vaccine, most studies have focused only on a few types of immune cells and pathways or mainly on the primary adaptive immune response to YF-17D vaccination. Here, we examined humoral, innate and adaptive cellular responses in a longitudinal YF-17D vaccination study in Switzerland, comparing both primary and booster vaccination. In contrast to the strong innate and adaptive immune response to the primary vaccination, we find that the response to boosting is much reduced. Our data show an inverse association of neutralizing antibodies at baseline with vaccine virus replication and with the immune response upon boosting. These results suggest that booster vaccination may not have major immunological effects when neutralizing antibodies are present. Importantly, our study population was healthy adults in a non-endemic country and ultimately booster vaccine requirement must be assessed based on additional epidemiological and public health considerations in endemic areas. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
- Author
-
Chevalier, Mathieu F., Bohner, Perrine, Pieraerts, Claire, Lhermitte, Benoit, Gourmaud, Jolanta, Nobile, Antoine, Rotman, Samuel, Cesson, Valerie, Martin, Virginie, Legris, Anne-Sophie, Dartiguenave, Florence, Gharbi, Dalila, De Leval, Laurence, Speiser, Daniel E., Nardelli-Haefliger, Denise, Jichlinski, Patrice, and Derré, Laurent
- Subjects
- *
IMMUNOREGULATION , *ANTIGEN presenting cells , *DENDRITIC cells , *INCURABLE diseases , *ONCOLOGY - Abstract
Blockade of inhibitory receptors (IRs) overexpressed by T cells can activate antitumor immune responses, resulting in the most promising therapeutic approaches, particularly in bladder cancer, currently able to extend patient survival. Thanks to their ability to cross-present antigens to T cells, dendritic cells (DCs) are an immune cell population that plays a central role in the generation of effective antitumor T-cell responses. While IR function and expression have been investigated in T cells, very few data are available for DCs. Therefore, we analyzed whether DCs express IRs that can decrease their functions. To this end, we investigated several IRs (PD-1, CTLA-4, BTLA, TIM-3, and CD160) in circulating CD1c + DCs, CD141 + DCs, and plasmacytoid DCs from healthy donors and patients with urothelial cancer (UCa). Different DC subsets expressed BTLA and TIM-3 but not other IRs. More importantly, BTLA and TIM-3 were significantly upregulated in DCs from blood of UCa patients. Locally, bladder tumor–infiltrating DCs also overexpressed BTLA and TIM-3 compared to DCs from paired nontumoral tissue. Finally, in vitro functional experiments showed that ligand-mediated engagement of BTLA and TIM-3 receptors significantly reduced the secretion of effector cytokines by DC subpopulations. Our findings demonstrate that UCa induces local and systemic overexpression of BTLA and TIM-3 by DCs that may result in their functional inhibition, highlighting these receptors as potential targets for UCa treatment. Patient summary We investigated the expression and function of a panel of inhibitory receptors in dendritic cells (DCs), an immune cell subpopulation critical in initiation of protective immune responses, among patients with urothelial carcinoma. We found high expression of BTLA and TIM-3 by blood and tumor DCs, which could potentially mediate decreased DC function. The results suggest that BTLA and TIM-3 might be new targets for urothelial carcinoma treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy.
- Author
-
Tcyganov, Evgenii N., Sanseviero, Emilio, Marvel, Douglas, Beer, Thomas, Tang, Hsin-Yao, Hembach, Peter, Speicher, David W., Zhang, Qianfei, Donthireddy, Laxminarasimha R., Mostafa, Ali, Tsyganova, Sabina, Pisarev, Vladimir, Laufer, Terri, Ignatov, Dmitriy, Ferrone, Soldano, Meyer, Christiane, Maby-El Hajjami, Hélène, Speiser, Daniel E., Altiok, Sooner, and Antonia, Scott
- Subjects
- *
CYTOTOXIC T cells , *TUMOR microenvironment , *PEROXYNITRITE , *IMMUNOTHERAPY , *MYELOID cells , *ANTIGENS - Abstract
Cancer immunotherapy often depends on recognition of peptide epitopes by cytotoxic T lymphocytes (CTLs). The tumor microenvironment (TME) is enriched for peroxynitrite (PNT), a potent oxidant produced by infiltrating myeloid cells and some tumor cells. We demonstrate that PNT alters the profile of MHC class I bound peptides presented on tumor cells. Only CTLs specific for PNT-resistant peptides have a strong antitumor effect in vivo , whereas CTLs specific for PNT-sensitive peptides are not effective. Therapeutic targeting of PNT in mice reduces resistance of tumor cells to CTLs. Melanoma patients with low PNT activity in their tumors demonstrate a better clinical response to immunotherapy than patients with high PNT activity. Our data suggest that intratumoral PNT activity should be considered for the design of neoantigen-based therapy and also may be an important immunotherapeutic target. [Display omitted] • PNT alters the profile of MHC class I peptides on tumor cells • Only CTLs specific for PNT-resistant peptides have a strong antitumor effect • Therapeutic targeting of PNT in mice reduces resistance of tumor cells to CTLs • High PNT in tumors is associated with worse clinical response to immunotherapy Tcyganov et al. demonstrate that peroxynitrite (PNT) in the tumor microenvironment alters the profile of MHC class I bound peptides on tumor cells. This makes recognition of tumor cells by cytotoxic T lymphocytes much less efficient and negatively impacts antitumor response. This suggests that PNT-resistant peptides are better suited for vaccination and that targeting of tumor cell resistance may include inhibition of PNT production. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Cysteine-rich Domain 1 of CD40 Mediates Receptor Self-assembly.
- Author
-
Smulski, Cristian R., Beyrath, Julien, Decossas, Marion, Chekkat, Neila, Wolff, Philippe, Estieu-Gionnet, Karine, Guichard, Gilles, Speiser, Daniel, Schneider, Pascal, and Fournel, Sylvie
- Subjects
- *
CD40 antigen , *B cells , *MACROPHAGES , *DENDRITIC cells , *LIGANDS (Biochemistry) - Abstract
The activation of CD40 on B cells, macrophages, and dendritic cells by its ligand CD154 (CD40L) is essential for the development of humoral and cellular immune responses. CD40L and other TNF superfamily ligands are noncovalent homotrimers, but the form under which CD40 exists in the absence of ligand remains to be elucidated. Here, we show that both cell surface-expressed and soluble CD40 self-assemble, most probably as noncovalent dimers. The cysteine-rich domain 1 (CRD1) of CD40 participated to dimerization and was also required for efficient receptor expression. Modelization of a CD40 dimer allowed the identification of lysine 29 in CRD1, whose mutation decreased CD40 self-interaction without affecting expression or response to ligand. When expressed alone, recombinant CD40-CRD1 bound CD40 with a KD of 0.6 μM. This molecule triggered expression of maturation markers on human dendritic cells and potentiated CD40L activity. These results suggest that CD40 self-assembly modulates signaling, possibly by maintaining the receptor in a quiescent state. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
- Author
-
Gillessen, Silke, Gnad-Vogt, Ulrike S., Gallerani, Elisa, Beck, Joachim, Sessa, Cristiana, Omlin, Aurelius, Mattiacci, Maria R., Liedert, Bernd, Kramer, Daniel, Laurent, Julien, Speiser, Daniel E., and Stupp, Roger
- Subjects
- *
ANTINEOPLASTIC agents , *TUMORS , *DESCRIPTIVE statistics - Abstract
Abstract: Background: EMD 521873 (Selectikine), an immunocytokine comprising a DNA-targeting antibody, aimed at tumour necrosis, fused with a genetically modified interleukin-2 (IL-2) moiety, was investigated in this first-in-human phase I study. Methods: Patients had metastatic or locally advanced solid tumours failing previous standard therapy. Selectikine was administered as a 1-hour intravenous infusion on 3 consecutive days, every 3weeks. A subgroup of patients also received 300mg/m2 cyclophosphamide on day 1 of each cycle. Escalating doses of Selectikine were investigated with the primary objective of determining the maximum tolerated dose (MTD). Results: Thirty-nine patients were treated with Selectikine alone at dose levels from 0.075 to 0.9mg/kg, and nine were treated at doses of 0.45 and 0.6mg/kg in combination with cyclophosphamide. A dose-dependent linear increase of peak serum concentrations and area under curve was found. The dose-limiting toxicity was grade 3 skin rash at the 0.9mg/kg dose-level; the MTD was 0.6mg/kg. Rash and flu-like symptoms were the most frequent side-effects. No severe cardiovascular side-effects (hypotension or vascular leak) were observed. At all dose-levels, transient increases in total lymphocyte, eosinophil and monocyte counts were recorded. No objective tumour responses, but long periods of disease stabilisation were observed. Transient and non-neutralising Selectikine antibodies were detected in 69% of patients. Conclusions: The MTD of Selectikine with or without cyclophosphamide administered under this schedule was 0.6mg/kg. The recommended phase II dose was 0.45–0.6mg/kg. Selectikine had a favourable safety profile and induced biological effects typical for IL-2. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
15. A stepwise protocol to coat aAPC beads prevents out-competition of anti-CD3 mAb and consequent experimental artefacts
- Author
-
Fuertes Marraco, Silvia A., Baumgaertner, Petra, Legat, Amandine, Rufer, Nathalie, and Speiser, Daniel E.
- Subjects
- *
ANTIGEN presenting cells , *ARTIFICIAL cells , *IMMUNOGLOBULINS , *IMMUNOASSAY , *CD3 antigen , *LABORATORY techniques - Abstract
Abstract: Artificial antigen-presenting cells (aAPC) are widely used for both clinical and basic research applications, as cell-based or bead-based scaffolds, combining immune synapse components of interest. Adequate and controlled preparation of aAPCs is crucial for subsequent immunoassays. We reveal that certain proteins such as activatory anti-CD3 antibody can be out-competed by other proteins (e.g. inhibitory receptor ligands such as PDL1:Fc) during the coating of aAPC beads, under the usually performed coating procedures. This may be misleading, as we found that decreased CD8 T cell activity was not due to inhibitory receptor triggering but rather because of unexpectedly low anti-CD3 antibody density on the beads upon co-incubation with inhibitory receptor ligands. We propose an optimized protocol, and emphasize the need to quality-control the coating of proteins on aAPC beads prior to their use in immunoassays. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
16. The three main stumbling blocks for anticancer T cells
- Author
-
Baitsch, Lukas, Fuertes-Marraco, Silvia A., Legat, Amandine, Meyer, Christiane, and Speiser, Daniel E.
- Subjects
- *
T cells , *CANCER immunotherapy , *CANCER invasiveness , *NATURAL immunity , *METASTASIS , *CELL receptors - Abstract
Memory and effector T cells have the potential to counteract cancer progression, but often fail to control the disease, essentially because of three main stumbling blocks. First, clonal deletion leads to relatively low numbers or low-to-intermediate T cell receptor (TCR) affinity of self/tumor-specific T cells. Second, the poor innate immune stimulation by solid tumors is responsible for inefficient priming and boosting. Third, T cells are suppressed in the tumor microenvironment by inhibitory signals from other immune cells, stroma and tumor cells, which induces T cell exhaustion, as demonstrated in metastases of melanoma patients. State-of-the-art adoptive cell transfer and active immunotherapy can partially overcome the three stumbling blocks. The reversibility of T cell exhaustion and novel molecular insights provide the basis for further improvements of clinical immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
17. Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+ T Cell Responsiveness.
- Author
-
Irving, Melita, Zoete, Vincent, Hebeisen, Michael, Schmid, Daphné, Baumgartner, Petra, Guillaume, Philippe, Romero, Pedro, Speiser, Daniel, Luescher, Immanuel, Rufer, Nathalie, and Michielin, Olivier
- Subjects
- *
T cell receptors , *CELL receptors , *PHYSIOLOGICAL effects of peptides , *HISTOCOMPATIBILITY , *IMMUNOLOGICAL tolerance , *HUMAN genetics , *CELL physiology - Abstract
Through a rational design approach, we generated a panel of HLA-A*0201/NY-ESO-1157-165-specific T cell receptors (TCR) with increasing affinities of up to 150-fold from the wild-type TCR. Using these TCR variants which extend just beyond the natural affinity range, along with an extreme supraphysiologic one having 1400-fold enhanced affinity, and a low-binding one, we sought to determine the effect of TCR binding properties along with cognate peptide concentration on CD8+ T cell responsiveness. Major histocompatibility complexes (MHC) expressed on the surface of various antigen presenting cells were peptide-pulsed and used to stimulate human CD8+ T cells expressing the different TCR via lentiviral transduction. At intermediate peptide concentration we measured maximum cytokine/chemokine secretion, cytotoxicity, and Ca2+ flux for CD8+ T cells expressing TCR within a dissociation constant (KD) range of ~1-5μM. Under these same conditions there was a gradual attenuation in activity for supraphysiologic affinity TCR with KD<~1μM, irrespective of CD8 co-engagement and of half-life (t1/2 = ln 2/koff) values. With increased peptide concentration, however, the activity levels of CD8+ T cells expressing expressing supraphysiologic affinity TCR were gradually restored. Together our data support the productive hit rate model of T cell activation arguing that it is not the absolute number of TCR/ pMHC complexes formed at equilibrium, but rather their productive turnover, that controls levels of biological activity. Our findings have important implications for various immunotherapies under development such as adoptive cell transfer of TCRengineered CD8+ T cells, as well as for peptide vaccination strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Reversible Major Histocompatibility Complex I-Peptide Multimers Containing Ni2+-Nitrilotriacetic Acid Peptides and Histidine Tags Improve Analysis and Sorting of CD8+ T Cells.
- Author
-
Schmidt, Julien, Guillaume, Philippe, Irving, Melita, Baumgaertner, Petra, Speiser, Daniel, and Luescher, Immanuel F.
- Subjects
- *
HISTOCOMPATIBILITY , *NITRILOTRIACETIC acid , *PEPTIDES , *PHYCOERYTHRIN , *STREPTAVIDIN , *T cell receptors , *HISTIDINE , *SURFACE plasmon resonance - Abstract
MHC-peptide multimers containing biotinylated MHC-peptide complexes bound to phycoerythrin (PE) streptavidin (SA) are widely used for analyzing and sorting antigen-specific T cells. Here we describe alternative T cell-staining reagents that are superior to conventional reagents. They are built on reversible chelate complexes of Ni2+-nitrilotriacetic acid (NTA) with oligohistidines. We synthesized biotinylated linear mono-, di-, and tetra-NTA compounds using conventional solid phase peptide chemistry and studied their interaction with HLA-A*0201-peptide complexes containing a His6, His12, or 2×His6 tag by surface plasmon resonance on SA-coated sensor chips and equilibrium dialysis. The binding avidity increased in the order His6 < His12 < 2×His6 and NTA1 < NTA2 < NTA4, respectively, depending on the configuration of the NTA moieties and increased to picomolar KD for the combination of a 2×His6 tag and a 2×Ni2+-NTA2. We demonstrate that HLA-A2-2×His6-peptide multimers containing either Ni2+-NTA4-biotin and PE-SA- or PE-NTA4-stained influenza and Melan A-specific CD8+ T cells equal or better than conventional multimers. Although these complexes were highly stable, they very rapidly dissociated in the presence of imidazole, which allowed sorting of bona fide antigen-specific CD8+ T cells without inducing T cell death as well as assessment of HLA-A2-peptide monomer dissociation kinetics on CD8+ T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
19. Tissue Homing and Persistence of Defined Antigen-Specific CD8+ Tumor-Reactive T-Cell Clones in Long-Term Melanoma Survivors.
- Author
-
Le Gal, Frédérique-Anne, Widmer, Valérie M., Dutoit, Valérie, Rubio-Godoy, Verena, Schrenzel, Jacques, Walker, Paul R., Romero, Pedro J., Valmori, Danila, Speiser, Daniel E., and Dietrich, Pierre-Yves
- Subjects
- *
CANCER patients , *IMMUNE response , *MELANOMA , *NEUROENDOCRINE tumors , *ANTIGENS , *PEPTIDES , *PHENOTYPES , *LONGITUDINAL method - Abstract
Tumor antigen-specific cytotoxic T cells (CTLs) play a major role in the adaptive immune response to cancers. This CTL response is often insufficient because of functional impairment, tumor escape mechanisms, or inhibitory tumor microenvironment. However, little is known about the fate of given tumor-specific CTL clones in cancer patients. Studies in patients with favorable outcomes may be very informative. In this longitudinal study, we tracked, quantified, and characterized functionally defined antigen-specific T-cell clones ex vivo, in peripheral blood and at tumor sites, in two long-term melanoma survivors. MAGE-A10-specific CD8+ T-cell clones with high avidity to antigenic peptide and tumor lytic capabilities persisted in peripheral blood over more than 10 years, with quantitative variations correlating with the clinical course. These clones were also found in emerging metastases, and, in one patient, circulating clonal T cells displayed a fully differentiated effector phenotype at the time of relapse. Longevity, tumor homing, differentiation phenotype, and quantitative adaptation to the disease phases suggest the contribution of the tracked tumor-reactive clones in the tumor control of these long-term metastatic survivor patients. Focusing research on patients with favorable outcomes may help to identify parameters that are crucial for an efficient antitumor response and to optimize cancer immunotherapy.Journal of Investigative Dermatology (2007) 127, 622–629. doi:10.1038/sj.jid.5700580; published online 12 October 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
20. Dextramers: New generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells
- Author
-
Batard, Pascal, Peterson, Daniel A., Devêvre, Estelle, Guillaume, Philippe, Cerottini, Jean-Charles, Rimoldi, Donata, Speiser, Daniel E., Winther, Lars, and Romero, Pedro
- Subjects
- *
T cells , *MAJOR histocompatibility complex , *EPSTEIN-Barr virus , *HLA histocompatibility antigens - Abstract
Abstract: Direct identification as well as isolation of antigen-specific T cells became possible since the development of “tetramers” based on avidin–fluorochrome conjugates associated with mono-biotinylated class I MHC–peptide monomeric complexes. In principle, a series of distinct class I MHC–peptide tetramers, each labelled with a different fluorochrome, would allow to simultaneously enumerate as many unique antigen-specific CD8+ T cells. Practically, however, only phycoerythrin and allophycocyanin conjugated tetramers have been generally available, imposing serious constraints for multiple labeling. To overcome this limitation, we have developed dextramers which are multimers based on a dextran backbone bearing multiple fluorescein and streptavidin moieties. Here we demonstrate the functionality and optimization of these new probes on human CD8+ T cell clones with four independent antigen specificities. Their applications to the analysis of relatively low frequency antigen-specific T cells in peripheral blood, as well as their use in fluorescence microscopy, are demonstrated. The data show that dextramers produce a stronger signal than their fluoresceinated tetramer counterparts. Thus, these could become the reagents of choice as the antigen-specific T cell labeling transitions from basic research to clinical application. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
21. Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples
- Author
-
Appay, Victor, Reynard, Severine, Voelter, Verena, Romero, Pedro, Speiser, Daniel E., and Leyvraz, Serge
- Subjects
- *
T cells , *LYMPHOCYTES , *PATHOGENIC microorganisms , *BLOOD testing - Abstract
Abstract: The study of natural T cell responses against pathogens or tumors, as well as the assessment of new immunotherapy strategies aimed at boosting these responses, requires increasingly precise ex vivo analysis of blood samples. For practical reasons, studies are often performed using purified PBMC samples, usually cryopreserved. Here, we report on FACS analyses of peripheral blood T cells, performed by direct antibody staining of non-purified total blood. For comparison, fresh PBMC, purified by Ficoll, were analysed. Our results show that the latter method can induce a bias in subpopulation distribution, in particular of CD8+ T cells, and sometimes lead to inaccurate measurement of antigen specific CD8+ T cell responses. Direct analysis of total blood can be applied to longitudinal immuno-monitoring of T cell-based therapy. While the need to purify and cryopreserve PBMC for subsequent studies is obvious, the use of whole blood has the advantage of providing unbiased results and only small amounts of blood are used. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
22. Melan-A/MART-1-specific CD8 T cells: from thymus to tumor
- Author
-
Pittet, Mikaël J., Zippelius, Alfred, Valmori, Danila, Speiser, Daniel E., Cerottini, Jean-Charles, and Romero, Pedro
- Subjects
- *
T cells , *MELANOMA , *ANTIGENS , *TUMORS - Abstract
The self-antigen Melan-A/MART-1 is frequently involved in T-cell responses against malignant melanoma. The use of fluorescent tetramers incorporating the immunodominant Melan-A/MART-1 peptide has provided new insights into HLA-A2-restricted T-cell responses against this antigen in cancer patients and in healthy individuals. Direct evidence has been provided that a large Melan-A/MART-1-specific CD8 T-cell pool is generated during thymic selection. Although several other examples of naive self-peptide-specific T-cell repertoires are known, this is the only one directly accessible to analysis in healthy individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
23. The orbital hoods of snapping shrimp have surface features that may represent tradeoffs between vision and protection.
- Author
-
Kingston, Alexandra C.N., Chappell, Daniel R., Koch, Loann, Johnsen, Sönke, and Speiser, Daniel I.
- Subjects
- *
SHRIMPS , *DECAPODA , *LIGHT scattering , *CONTACT angle , *SHOCK waves , *WHITE spot syndrome virus - Abstract
Snapping shrimp (Alpheidae) are decapod crustaceans named for the snapping claws with which they produce cavitation bubbles. Snapping shrimp use the shock waves released by collapsing cavitation bubbles as weapons. Along with their distinctive claws, snapping shrimp have orbital hoods, extensions of their carapace that cover their heads and eyes. Snapping shrimp view the world through their orbital hoods, so we asked if the surfaces of the orbital hoods of the snapping shrimp Alpheus heterochaelis have features that minimize the scattering of light. Using SEM, we found that surface features, primarily microbial epibionts, covered less space on the surfaces of the orbital hoods of A. heterochaelis (∼18%) than they do elsewhere on the carapace (∼50%). Next, we asked if these surface features influence aerophobicity. By measuring the contact angles of air bubbles, we found the orbital hoods of A. heterochaelis are less aerophobic than other regions of the carapace. Surfaces that are less aerophobic are more likely to have cavitation bubbles adhere to them and are more likely to have shock waves cause new cavitation bubbles to nucleate upon them. Computational modeling indicates the orbital hoods of A. heterochaelis face a functional trade-off: fewer surface features, such as less extensive communities of microbial epibionts, may minimize the scattering of light at the cost of making the adhesion and nucleation of cavitation bubbles more likely. • Surface features in snapping shrimp vary between the orbital hood and carapace. • The orbital hoods of A. heterochaelis are less aerophobic than the carapace. • Most surface features in snapping shrimp appear to be microbial in nature. • Modeling suggests these surface features affect light scattering and aerophobicity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly.
- Author
-
Saavedra, Danay, Fuertes, Silvia A., Suárez, Gisela M., González, Amnely, Lorenzo-Luaces, Patricia, García, Beatriz, Aznar, Elisa, Mazorra, Zaima, Crombet, Tania, Speiser, Daniel E., and Lage, Agustin
- Subjects
- *
CD4 antigen , *CD8 antigen , *T cells , *IMMUNOSENESCENCE , *CYTOKINES - Abstract
The changes that occur in the immune system with aging are commonly termed immunosenescence. Immunosenescence affects almost all components and functions of the immune response. The most commonly described change is a decrease in numbers and proportions of naïve T cells combined with the increase of terminally differentiated T lymphocytes, mainly affecting CD8+ T cells. The changes in the naïve T cell compartment are principally attributed to thymic involution and lifelong chronic antigen stimulation, among other triggers. Several strategies such as hormonal products, thymic peptides, or cytokines have been proposed for the restoration of the immune system. Here we show the effects of Biomodulina T (BT) on several populations of the immune system when administered to elderly patients diagnosed with recurrent respiratory infections. BT is a polypeptide fraction of bovine thymus, a Cuban product that obtained sanitary registration in 1994 for its immunomodulatory effects. We found that CD4+ naïve T, CD8+ stem cell-like memory (SCM) T, CD4+ recent thymic emigrants (RTE) T and CD4+ CD31+ naïve T cells increased with the administration of BT, whereas CD4+ and CD8+ T cells expressing PD1 decreased after the treatment with BT. Additionally, the proliferative capacity of CD4+ T cells measured by Ki67 expression, and the CD4+ T cell ability to produce IFN-γ were also improved by BT. Moreover, BT did not increase CD4+ Tregs. Altogether, these findings suggest that BT administration is a promising strategy for immune restoration in elderly patients and improvement of immunotherapeutic potential in cancer patients. Biomodulina T administered in elderly patients: • Expanded naïve CD4+ T cells, RTE and CD8+ SCM T cells. • Decreased CD4+ and CD8+ T cells expressing PD1 • Did not expand Tregs • Is a promising strategy for the improvement of immunotherapy in cancer patients [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Therapeutic cancer vaccines based on molecularly defined human tumor antigens
- Author
-
Romero, Pedro, Pittet, Mikael, Dutoit, Valerie, Zippelius, Alfred, Liénard, Danielle, Lejeune, Ferdy, Guillaume, Philippe, Rimoldi, Donata, Valmori, Danila, Speiser, Daniel E., and Cerottini, Jean-Charles
- Subjects
- *
VACCINES , *CANCER vaccines , *T cells - Abstract
The results of numerous phases I and II clinical trials testing the safety and immunogenicity of various cancer vaccine formulations based on cytolytic T lymphocytes (CTLs)-defined tumor antigens have been reported recently. Specific T cell responses can be detected in only a fraction of immunized patients. A smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring anti-tumor responses and at sustaining a large contingent of tumor antigen-specific and fully functional effector T cells at tumor sites. [Copyright &y& Elsevier]
- Published
- 2002
26. Degeneracy instead of specificity: is this a solution to cancer immunotherapy?
- Author
-
Pittet, Mikaël J., Zippelius, Alfred, Valmori, Danila, Speiser, Daniel E., Cerottini, Jean-Charles, and Romero, Pedro
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.